- ISIN
- US98419J3059
- CUSIP
- 98419J305
- Delisting Date
- Jul 15, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 16, 2020
Highlights
- Market Cap
- $301.34M
- Enterprise Value
- $356.88M
- EPS (TTM)
- $1.89
- PE Ratio
- 13.21
- PEG Ratio
- 0.05
- Total Revenue (TTM)
- $48.56M
- Gross Profit (TTM)
- $46.00M
- EBITDA (TTM)
- $7.40M
- Year Range
- $24.93 - $30.00
- ROA (TTM)
- 12.44%
- ROE (TTM)
- 36.40%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
XOMAP Performance Chart
Loading charts...
Compare this symbol against anything
Returns By Period
XOMA Corporation (XOMAP) has returned -1.09% so far this year and 5.55% over the past 12 months.
XOMA Corporation
- 1D
- 0.00%
- 1M
- 0.04%
- 6M
- 0.17%
- YTD
- -1.09%
- 1Y
- 5.55%
- 3Y*
- 8.96%
- 5Y*
- 7.87%
- 10Y*
- —
- ALL TIME*
- 8.88%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
XOMAP Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.26% | -0.54% | 1.58% | -2.02% | 0.93% | 0.07% | 0.19% | -1.09% | |||||
| 2025 | 1.22% | 0.69% | 0.05% | 1.56% | 0.41% | 0.45% | 1.06% | 2.14% | 1.03% | 0.58% | 2.06% | 0.94% | 12.86% |
| 2024 | 1.48% | -0.95% | 1.36% | 0.73% | 1.31% | 0.83% | 1.18% | -0.01% | 3.17% | 1.66% | -1.12% | 0.74% | 10.81% |
| 2023 | 3.86% | 0.56% | -3.04% | 0.79% | -2.97% | 5.69% | 0.45% | -2.54% | 0.63% | -6.56% | 5.21% | 10.48% | 11.98% |
| 2022 | 0.25% | -2.05% | 6.21% | 0.07% | -2.88% | 1.36% | 2.83% | -1.49% | -3.35% | -5.51% | 4.31% | 3.47% | 2.56% |
| 2021 | 0.96% | 0.91% | 1.06% | 1.82% | 0.05% | 4.24% | 0.53% | 0.25% | 3.03% | -0.72% | -0.34% | 0.38% | 12.76% |
Benchmark Metrics
XOMA Corporation has an annualized alpha of 8.83%, beta of 0.08, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since December 16, 2020.
- This stock captured 24.81% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -1.31%) - a profile typical of hedging or uncorrelated assets.
- Beta of 0.08 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 8.83%
- Beta
- 0.08
- R²
- 0.01
- Upside Capture
- 24.81%
- Downside Capture
- -1.31%
Return for Risk
Risk / Return Rank
XOMAP ranks 58 for risk / return — above 58% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for XOMA Corporation (XOMAP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XOMAP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.96 | ||
| Sortino ratioReturn per unit of downside risk | -1.24 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.25 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.72 | 2.00 | -1.28 |
| Martin ratioReturn relative to average drawdown | 1.36 | 8.49 | -7.13 |
Dividends
Dividend History
XOMA Corporation provided a 8.63% dividend yield over the last twelve months, with an annual payout of $2.16 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Dividend | $2.16 | $2.16 | $2.16 | $2.16 | $2.14 | $1.80 |
Dividend yield | 8.63% | 8.02% | 8.33% | 8.49% | 8.63% | 6.83% |
Monthly Dividends
The table displays the monthly dividend distributions for XOMA Corporation. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $0.54 | $1.62 | |||||
| 2025 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $2.16 |
| 2024 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $2.16 |
| 2023 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.54 | $0.00 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $2.16 |
| 2022 | $0.52 | $0.00 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $0.54 | $0.00 | $0.00 | $0.00 | $2.14 |
| 2021 | $0.72 | $0.00 | $0.00 | $0.00 | $0.54 | $0.00 | $0.54 | $0.00 | $0.00 | $0.00 | $1.80 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the XOMA Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the XOMA Corporation was 14.28%, occurring on Oct 25, 2022. Recovery took 175 trading sessions.
The current XOMA Corporation drawdown is 6.35%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-14.28%Oct 2022 | 2mo 29d | 8mo 18d | 11mo 17dJul 2022 - Jul 2023 | Bear market2022 |
-12.49%Oct 2023 | 3mo 16d | 1mo 22d | 5mo 8dJul 2023 - Dec 2023 | — |
-7.45%Apr 2026 | 20d | — | 3mo 25dApr 2026 - now | — |
-6.17%May 2022 | 1mo 7d | 2mo | 3mo 7dApr 2022 - Jul 2022 | Bear market2022 |
-5.57%Mar 2026 | 2mo 14d | 17d | 3mo 1dJan 2026 - Apr 2026 | — |
Drawdown Indicators
| XOMAP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -14.28% | -56.78% | +42.50% |
Max Drawdown (1Y)Largest decline over 1 year | -7.45% | -9.10% | +1.65% |
Max Drawdown (3Y)Largest decline over 3 years | -10.83% | -18.90% | +8.07% |
Max Drawdown (5Y)Largest decline over 5 years | -14.28% | -25.43% | +11.15% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -6.35% | -1.58% | -4.77% |
Average DrawdownAverage peak-to-trough decline | -2.85% | -10.70% | +7.85% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.95% | 2.14% | +1.81% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of XOMA Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how XOMA Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for XOMAP, comparing it with other companies in the Biotechnology industry. Currently, XOMAP has a P/E ratio of 13.2. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for XOMAP compared to other companies in the Biotechnology industry. XOMAP currently has a PEG ratio of 0.1. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for XOMAP relative to other companies in the Biotechnology industry. Currently, XOMAP has a P/S ratio of 9.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for XOMAP in comparison with other companies in the Biotechnology industry. Currently, XOMAP has a P/B value of 4.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with XOMAP
Add XOMA Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with XOMAP